Table 2.
Analysis of the combined effects of taxol and Rosco on human colorectal cancer cell lines
| Combined treatment of taxol and Rosco |
Combination interaction at various durations of treatment in human colorectal cancer cells1 |
||||||||
| SW48 | SW1116 | SW837 | |||||||
| 2 d | 4 d | 6 d | 2 d | 4 d | 6 d | 2 d | 4 d | 6 d | |
| Taxol 0.5 IC50 + Rosco 1.0 μg/mL | ant | ant | ant | ant | ant | syn | ant | ant | syn |
| Taxol 1.0 IC50 + Rosco 10 μg/mL | ant | ant | add | ant | ant | ant | ant | ant | syn |
| Taxol 2.0 IC50 + Rosco 15 μg/mL | ant | ant | ant | syn | ant | ant | ant | ant | ant |
| Taxol 3.0 IC50 + Rosco 20 μg/mL | ant | ant | ant | ant | ant | ant | ant | ant | ant |
| Taxol 4.0 IC50 + Rosco 25 μg/mL | ant | add | add | syn | ant | add | ant | ant | ant |
1
The data are based on the mean of absorbance measurements of 3 independent experiments. ant: Antagonistic; add: Additive; syn: Synergistic.